Companies · Biotechnology

Steep Hill, Inc.

BERKELEY · Biotechnology

Diligence memoA one-page analyst read on Steep Hill, Inc. — recommendation, valuation, rhythm, risks.
$10.1M
Total raised · real
4
Rounds
1.0×
Latest step-up
Top 44%
Sector rank · raised
Series A
Latest stage · inferred · Wed Jul 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Steep Hill, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.80× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
  • Within the normal band (80% of peer median) for its niche.
Dormant
  • Last raise 7.0 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Steep Hill, Inc. is one of 4293 Biotechnology companies tracked from BERKELEY. By capital raised it ranks mid-pack (ahead of 57% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
14
Investors (latest)
2014
Year incorporated
2019-07-03
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2015-06-15 Raised $1.0M (real) Modeled valuation $44M (est)$1.0M$44MSeed2015Seed · 2017-03-07 Raised $1.0M (real) Modeled valuation $44M (est)$1.0M$44MSeed2017Series A · 2018-10-25 Raised $4.1M (real) Modeled valuation $147M (est)$4.1M$147MSeries A2018Series A · 2019-07-03 Raised $4.0M (real) Modeled valuation $145M (est)$4.0M$145MSeries A2019+$1.0M+$4.1M+$4.0MCumulative $10M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.0M · 2015
Seed extension$1.0M · 2017
Series A$4.1M · 2018
Series A extension$4.0M · 2019

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$144.6M
Base estimate est.
$4.4M
Conservative case
$786.3M
Upside case
$18.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $44.4M · 2015-06-152015Seed · modeled $44.4M · 2017-03-07Series A · modeled $147.1M · 2018-10-25Series A · modeled $144.6M · 2019-07-032019
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
7.0 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
16 mo
Avg between rounds
$2.5M/yr
Capital velocity
11.0 yr
On record since
2015
First round
4
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.4× above median
This company$10.1M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.7× of median
This company$4.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 2.3× above median
This company$144.6M
Sector median$64.2M

Raised more than 57% of sector peers (real $). Modeled value above 66% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #139 of 216.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)TRACT Therapeutics, Inc. · Series A Raised $15.0M · modeled $542.3M (est)TechAccel, LLC · Series A Raised $15.0M · modeled $542.3M (est)Arrakis Therapeutics, Inc. · Series A Raised $28.2M · modeled $542.3M (est)Trident Labs, Inc. · Series A Raised $14.0M · modeled $506.1M (est)Meissa Vaccines Inc · Series A Raised $15.2M · modeled $503.1M (est)Vibe Bioscience Ltd. · Series A Raised $13.9M · modeled $501.1M (est)Trovagene, Inc. · Series A Raised $45.3M · modeled $488.0M (est)Taiga Biotechnologies, Inc. · Series A Raised $37.9M · modeled $485.3M (est)Equinox, Inc. · Series A Raised $34.7M · modeled $485.2M (est)Aruna Biomedical Inc · Series A Raised $22.4M · modeled $480.5M (est)Vibe Bioscience Corp · Series A Raised $13.7M · modeled $476.8M (est)Adarza BioSystems, Inc. · Series A Raised $31.5M · modeled $461.9M (est)Steep Hill, Inc. (this company) Raised $10.1M · modeled $144.6M (est)Steep Hill, Inc.
CompanyStageRaised · realValue · estvs peer med.
TRACT Therapeutics, Inc.Series A$15.0M$542.3M3.00×
TechAccel, LLCSeries A$15.0M$542.3M3.00×
Arrakis Therapeutics, Inc.Series A$28.2M$542.3M3.00×
Trident Labs, Inc.Series A$14.0M$506.1M2.80×
Meissa Vaccines IncSeries A$15.2M$503.1M2.78×
Vibe Bioscience Ltd.Series A$13.9M$501.1M2.77×
Trovagene, Inc.Series A$45.3M$488.0M2.70×
Taiga Biotechnologies, Inc.Series A$37.9M$485.3M2.68×
Equinox, Inc.Series A$34.7M$485.2M2.68×
Aruna Biomedical IncSeries A$22.4M$480.5M2.66×
Vibe Bioscience CorpSeries A$13.7M$476.8M2.64×
Adarza BioSystems, Inc.Series A$31.5M$461.9M2.56×
Steep Hill, Inc. this companySeries A$10.1M$144.6M0.80×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.0M2015-06-15$5.0M$44.4M85%
Seed$1.0M2017-03-07$5.0M$44.4M90%
Series A$4.1M2018-10-25$18.5M$147.1M90%
Series A$4.0M2019-07-03$18.2M$144.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.0M2015-06-15
    • First recorded raise — entered as Seed.
    • 11 investors on this round.
  2. Seed$1.0M2017-03-07
    • Raised again after 21 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • Switched to Rule 506(b) (was Rule 506(c)).
    • 1 investor on this round.
  3. Series A$4.1M2018-10-25
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 4.1× larger than the prior — scaling up.
    • 18 investors on this round.
  4. Series A$4.0M2019-07-03
    • Raised 8 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 14 investors on this round.
Intelligence
2020 ~Q4
Modeled next raise · ~16mo cadence
$4.0M
Modeled next size est.range $4.0M$6.4M
1.0×
Last step-up
$2.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Mitchell Baruchowitz7 other2018-10
David Lampach1 other2015-06
Mitchell Kulick1 other2015-06
Nigel Stobart1 other2019-07
Stephen DeAngelo1 other2015-06
Addison Demoura2015-06
Andrew Rosenstein2018-10
Brett Finkelstein2018-10
Jeffrey Monat2018-10
Jmichaele Keller2017-03
Stephen Finfer2018-10
Registry & provenance

Steep Hill, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1649526
SEC CIK
2014
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Launchpad Therapeutics, Inc.BiotechnologySeries A$10.0M$111.5Msame sector · same stage
DOSE Therapeutics, Inc.BiotechnologySeries A$10.0M$149.7Msame sector · same stage
ImmuneSensor Therapeutics, Inc.BiotechnologySeries A$10.0M$114.6Msame sector · same stage
Innervace, Inc.BiotechnologySeries A$10.0M$131.2Msame sector · same stage
U1 Bio, Inc.BiotechnologySeries A$9.9M$136.5Msame sector · same stage
Greenstone Biosciences, Inc.BiotechnologySeries A$10.2M$158.7Msame sector · same stage
Recros Medica, Inc.BiotechnologySeries A$9.9M$149.0Msame sector · same stage
Advanced Nanotherapies Inc.BiotechnologySeries A$9.9M$156.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Hilltop Biosciences Inc.BiotechnologySeries A$22.9M90%
Medical 21, Inc.BiotechnologySeries A$102.9M86%
Gradient Pharmaceuticals, Inc.BiotechnologyPre-Seed$46.9M86%
Summit Biolabs, Inc.BiotechnologyPre-Seed$11.9M84%
Hillhurst Biopharmaceuticals, Inc.BiotechnologySeed$13.9M84%
Quarry Heme, IncBiotechnologySeries A$33.0M84%
Summit Street Medical LLCBiotechnologySeed$82.6M84%
Forte Biosciences, Inc.BiotechnologySeries B$771.4M84%
Frequently asked
How much funding has Steep Hill, Inc. raised?
Steep Hill, Inc. has raised approximately $10.1M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Steep Hill, Inc.'s estimated valuation?
Provath's modeled valuation for Steep Hill, Inc. is approximately $144.6M (modeled range $4.4M–$786.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Steep Hill, Inc. at?
Steep Hill, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Wed Jul 03.
What does Steep Hill, Inc. do and where is it based?
Steep Hill, Inc. operates in the Biotechnology sector, based in BERKELEY.
Explore related

See where Steep Hill, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Steep Hill, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.